News for GILEAD SCIENCES (GILDD.BA)

With the policy overhang, earnings guidance will be closely watched during the second busiest week. Markets are likely to be dominated by earnings and tariff news.

Based on the search results, I now have enough information to create a comprehensive market recap article for April 18, 2025. I'll focus on the current market

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined ‘The Exchange’ on […]

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved success. To appreciate Iovance's opportunity, we need to first gain a basic understanding of the company's primary scientific focus.

**media[592903]**

Exploring the Strategic Moves of Parnassus Value Equity Fund (Trades, Portfolio) in Q1 2025 Parnassus Value Equity Fund (Trades, Portfolio) recently submitted

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Summary Gilead Sciences Inc (GILD), a leading biopharmaceutical company, has announced that it will release its first quarter 2025 financial results on Thursday

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 af

Gilead Sciences (GILD) to announce its Q1 2025 financial results on April 24, 2025, post-market close. A live webcast discussing the results will be hel

Shares of Gilead Sciences Inc (GILD) fell 4.16% in mid-day trading on Apr 10. The stock reached an intraday low of $99.25, before recovering slightly to $100.

NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a respo

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., April 10, 2025 Revenue-generating with an exciting, diversified, largely externally funded, advanced develop

PR NewswireSOUTH SAN FRANCISCO, Calif., April 10, 2025 Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodel

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its Russell 1000 Value benchmark, driven by detractors in the energy and financials, overcame contributions from overweight to energy and underweight to IT. […]

The biggest tail risk we are facing is a full-on trade war, which is why the market reacted so negatively to the so-called Liberation Day tariffs.

**media[589629]**

On April 3, 2025, Gilead Sciences Inc (GILD) announced its commitment to driving innovation in the fields of virology, oncology, and immunology. The company is